|
1
|
Ortmann CA and Mazhar D: Second-line
systemic therapy for metastatic urothelial carcinoma of the
bladder. Future Oncol. 9:1637–1651. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Choi YJ, Lee HJ, Kang DW, Han IH, Choi BK
and Cho WH: Ginsenoside Rg3 induces apoptosis in the U87MG human
glioblastoma cell line through the MEK signaling pathway and
reactive oxygen species. Oncol Rep. 30:1362–1370. 2013.PubMed/NCBI
|
|
3
|
Park HM, Kim SJ, Kim JS and Kang HS:
Reactive oxygen species mediated ginsenoside Rg3- and Rh2-induced
apoptosis in hepatoma cells through mitochondrial signaling
pathways. Food Chem Toxicol. 50:2736–2741. 2012. View Article : Google Scholar
|
|
4
|
Jiang JW, Chen XM, Chen XH and Zheng SS:
Ginsenoside Rg3 inhibit hepatocellular carcinoma growth via
intrinsic apoptotic pathway. World J Gastroenterol. 17:3605–3613.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang C, Liu L, Yu Y, Chen B, Tang C and
Li X: Antitumor effects of ginsenoside Rg3 on human hepatocellular
carcinoma cells. Mol Med Rep. 5:1295–1298. 2012.PubMed/NCBI
|
|
6
|
Byun SS, Kim SW, Choi H, Lee C and Lee E:
Augmentation of cisplatin sensitivity in cisplatin-resistant human
bladder cancer cells by modulating glutathione concentrations and
glutathione-related enzyme activities. BJU Int. 95:1086–1090. 2005.
View Article : Google Scholar
|
|
7
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar
|
|
8
|
Chou TC, Motzer RJ, Tong Y and Bosl GJ:
Computerized quantitation of synergism and antagonism of taxol,
topotecan, and cisplatin against human teratocarcinoma cell growth:
a rational approach to clinical protocol design. J Natl Cancer
Inst. 86:1517–1524. 1994. View Article : Google Scholar
|
|
9
|
Yoon CY, Park MJ, Lee JS, et al: The
histone deacetylase inhibitor trichostatin A synergistically
resensitizes a cisplatin resistant human bladder cancer cell line.
J Urol. 185:1102–1111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hong JH, Lee E, Hong J, Shin YJ and Ahn H:
Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder
cancer cell lines. BJU Int. 90:113–117. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sorenson CM, Barry MA and Eastman A:
Analysis of events associated with cell cycle arrest at
G2 phase and cell death induced by cisplatin. J Natl
Cancer Inst. 82:749–755. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
von der Maase H, Hansen SW, Roberts JT, et
al: Gemcitabine and cisplatin versus methotrexate, vinblastine,
doxorubicin, and cisplatin in advanced or metastatic bladder
cancer: results of a large, randomized, multinational, multicenter,
phase III study. J Clin Oncol. 18:3068–3077. 2000.
|
|
13
|
Loehrer PJ Sr, Einhorn LH, Elson PJ, et
al: A randomized comparison of cisplatin alone or in combination
with methotrexate, vinblastine, and doxorubicin in patients with
metastatic urothelial carcinoma: a cooperative group study. J Clin
Oncol. 10:1066–1073. 1992.
|
|
14
|
Logothetis CJ, Dexeus FH, Finn L, et al: A
prospective randomized trial comparing MVAC and CISCA chemotherapy
for patients with metastatic urothelial tumors. J Clin Oncol.
8:1050–1055. 1990.PubMed/NCBI
|
|
15
|
Sternberg CN, Yagoda A, Scher HI, et al:
Preliminary results of M-VAC (methotrexate, vinblastine,
doxorubicin and cisplatin) for transitional cell carcinoma of the
urothelium. J Urol. 133:403–407. 1985.PubMed/NCBI
|
|
16
|
Kim SM, Lee SY, Cho JS, et al: Combination
of ginsenoside Rg3 with docetaxel enhances the susceptibility of
prostate cancer cells via inhibition of NF-κB. Eur J Pharmacol.
631:1–9. 2010.PubMed/NCBI
|
|
17
|
Lee CK, Park KK, Chung AS and Chung WY:
Ginsenoside Rg3 enhances the chemosensitivity of tumors to
cisplatin by reducing the basal level of nuclear factor erythroid
2-related factor 2-mediated heme oxygenase-1/NAD(P)H quinone
oxidoreductase-1 and prevents normal tissue damage by scavenging
cisplatin-induced intracellular reactive oxygen species. Food Chem
Toxicol. 50:2565–2574. 2012.
|
|
18
|
Entrez Gene. CCNB1 cyclin B1. Accessed
January 15, 2014
|
|
19
|
Chen JX, Peng HM, Pu SP and Guo YP:
Inducement effect of ginsenoside Rg3 on apoptosis of human bladder
transitional cell carcinoma cell line EJ. Zhongguo Zhong Yao Za
Zhi. 32:1680–1684. 2007.(In Chinese).
|
|
20
|
Duggan BJ, Maxwell P, Kelly JD, et al: The
effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein
expression and apoptosis in human bladder transitional cell
carcinoma. J Urol. 166:1098–1105. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Touloupidis S, Fatles G, Kalaitzis C, et
al: The significance of p53 and bcl-2 overexpression and other
prognostic factors in transitional cell carcinoma of the bladder.
Int Urol Nephrol. 38:231–236. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Glick SH, Howell LP and White RW:
Relationship of p53 and bcl-2 to prognosis in muscle-invasive
transitional cell carcinoma of the bladder. J Urol. 155:1754–1757.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu TT, Chen JH, Lee YH and Huang JK: The
role of bcl-2, p53, and ki-67 index in predicting tumor recurrence
for low grade superficial transitional cell bladder carcinoma. J
Urol. 163:758–760. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Uchida T, Minei S, Gao JP, Wang C, Satoh T
and Baba S: Clinical significance of p53, MDM2 and bcl-2 expression
in transitional cell carcinoma of the bladder. Oncol Rep.
9:253–259. 2002.PubMed/NCBI
|
|
25
|
Bolenz C, Becker A, Trojan L, et al:
Optimizing chemotherapy for transitional cell carcinoma by
application of bcl-2 and bcl-xL antisense oligodeoxynucleotides.
Urol Oncol. 25:476–482. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Le Bras M, Rouy I and Brenner C: The
modulation of inter-organelle cross-talk to control apoptosis. Med
Chem. 2:1–12. 2006.PubMed/NCBI
|
